U-M startup Rubicon Genomics finds its niche in analysis kits

11/4/2015

Emerging tech companies call them pivots, a polite way of describing what is usually a drastic change in operations to figure out how to generate enough revenue to keep the lights on. When James Koziarz, a longtime executive at Abbott Laboratories, came out of retirement to take over as CEO of struggling Rubicon Genomics Inc. in December 2008, the company was in too much trouble for sugar-coated descriptions. The company, which spun out from the University of Michigan to do contract research for other companies, was near death and in need of a reinvention…